Sensei Biotherapeutics (HAM:407) Marketable Securities : €37.53 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sensei Biotherapeutics's Marketable Securities for the quarter that ended in Jun. 2024 was €37.53 Mil.

Sensei Biotherapeutics's annual Marketable Securities declined from Dec. 2021 (€124.31 Mil) to Dec. 2022 (€84.32 Mil) and declined from Dec. 2022 (€84.32 Mil) to Dec. 2023 (€48.37 Mil).

Sensei Biotherapeutics Marketable Securities Historical Data

The historical data trend for Sensei Biotherapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Marketable Securities Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

124.31

84.32

48.37

Sensei Biotherapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Marketable Securities	Get a 7-Day Free Trial															63.33	56.85	48.37	43.36	37.53

Sensei Biotherapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sensei Biotherapeutics (HAM:407) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sensei Biotherapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

SNSE:USA 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics Headlines

No Headlines